ArticleInternational dental journal2026
COL11A2 Methylation as a Biomarker for Radiosensitivity and Microenvironment Remodelling in Oral Squamous Cell Carcinoma.
Article in International dental journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiven that DNA methylation and the tumour microenvironment (TME) are both key contributors to tumour radiosensitivity, we aimed to identify specific differential DNA methylation patterns associated with oral squamous cell carcinoma (OSCC) prognosis and TME changes after radiation.
methodsDifferential methylation analysis was conducted using the Tissue Cancer Genome Atlas database (TCGA). Differential methylation positions (DMPs) and differentially methylated regions (DMRs) were identified between normal oral tissue and OSCC tissue. For screening and validating differentially methylated genes, interaction analysis, Kaplan-Meier (K-M) survival curves, Cox proportional hazards models, and linear regression were performed. Spline smoothing was used to analyse the correlation between XI collagen alpha-2 chain (COL11A2) methylation and overall survival post-radiotherapy. CIBERSORT and ESTIMATE algorithms were used to correlate COL11A2 methylation with immune infiltrates, following GSEA analysis to evaluate biological processes.
resultsCOL11A2 was identified from the top 10 DMPs and DMRs intersection. COL11A2 methylation showed a nonlinear relationship with OSCC survival, with two inflection points at β = 0.23 (P = .3430) and β = 0.35 (P = .0520). The K-M curve showed that COL11A2 methylation was negatively correlated with OSCC survival (P = .0458). The diagnostic association map revealed that radiotherapy was correlated with OSCC prognosis (P = .0202), with high methylation linked to better outcomes. High COL11A2 methylation was associated with increased immune cell infiltration, such as CD4+ T cells, CD8+ T cells, and NK cells. Enrichment analysis using DAVID identified the Hippo signalling pathway (P = .00001), TRP (P = .00014), and HPV signalling pathways (P = .00022) as significantly associated with COL11A2 methylation.
conclusionCOL11A2 methylation level shows promise as a predictor for post-radiotherapy prognosis in OSCC, potentially through its influence on immune cell infiltration and key signalling pathways. Further experiments are needed to confirm its role and mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.